CA1075600A - Immunoassay for thymopoietin - Google Patents
Immunoassay for thymopoietinInfo
- Publication number
- CA1075600A CA1075600A CA282,819A CA282819A CA1075600A CA 1075600 A CA1075600 A CA 1075600A CA 282819 A CA282819 A CA 282819A CA 1075600 A CA1075600 A CA 1075600A
- Authority
- CA
- Canada
- Prior art keywords
- thymopoietin
- antibody
- antigen
- labeled
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ABSTRACT
An immunoassay for the polypeptide thymic hormone thymopoietin is described. Determination of thymopoietin levels in biological fluids provides a useful diagnostic test for myasthenic gravis (elevated levels), immune deficiency disease (reduced levels), immunologically mediated disease such as rheumatoid arthritis, systemic lupus erythematosus and allergy (reduced levels), cancer (reduced levels), malnutrition (reduced levels) and infections (reduced levels).
The present assay is also useful as a monitor of the effective-ness of therapy in each of the aforementioned types of disease states.
An immunoassay for the polypeptide thymic hormone thymopoietin is described. Determination of thymopoietin levels in biological fluids provides a useful diagnostic test for myasthenic gravis (elevated levels), immune deficiency disease (reduced levels), immunologically mediated disease such as rheumatoid arthritis, systemic lupus erythematosus and allergy (reduced levels), cancer (reduced levels), malnutrition (reduced levels) and infections (reduced levels).
The present assay is also useful as a monitor of the effective-ness of therapy in each of the aforementioned types of disease states.
Description
~'7S~
BACKGROUND OF THE INVENTION
Thymopoie-tin is a polypeptide hormone of the thymus that indu¢es differen-tiation of prothymocytes to thymocytes and also has secondary effects on neuromuscular transmission.
Two forms of bovine thymopoietin, designated thymopoietin I
and II have been isolated and shown to be immunologically cross reactive. (Thymopoietin is now used in preference to the original name Thymin)~ See G. Goldstein, Nature 247, 11 ~197~).
Although thymopoietin can be detected by bioassay using either its effects on T cell differen-tiation or neuromuscular transmission, these assays are complex, time-consuming, and difficult to standardize. Moreover, unlike immunoassay, and particularly radioimmunoassay, bioassays are not readily automated and thus could not be routinely employed by clinical laboratories or other diagnostic facilities to screen large numbers of samples in an economic fashion.
DESCRIPTION OF lHE INVENTION
.
The present invention relates to an immunoassay for thymopoie-tin. A pre-ferred immunoassay can give sensitivities ZO ; down to about O.1 ng/ml. of -the hormone in biological fluid samples such as plasma or serum. Thus the instant assay can be employed as a diagnostic test for disease states which exhibit either elevated (myasthenia gravis) or reduced (aging, immune deficiency or immunologically mediated diseases, cancer, malnutrition, infect1ons and the like) levels of thymopoietin. The two forms of thymopoietin are indistinguishable in immunoassay procedures. ;
The antigen utilized~to prepare the antibody ~or the instant~assay is readily obtained by bonding thymopoietin to ~-an 1mmunogenlc carrier mater1al 1n a manner known per se. Such -bonding is pre~erably achieved by employing a suitable bifunctional ~ ;
l1nking graup. A preferred bifunctional linking group for this purpose 1S a C2 7 dialkanal such as glutaraldehyde.
BACKGROUND OF THE INVENTION
Thymopoie-tin is a polypeptide hormone of the thymus that indu¢es differen-tiation of prothymocytes to thymocytes and also has secondary effects on neuromuscular transmission.
Two forms of bovine thymopoietin, designated thymopoietin I
and II have been isolated and shown to be immunologically cross reactive. (Thymopoietin is now used in preference to the original name Thymin)~ See G. Goldstein, Nature 247, 11 ~197~).
Although thymopoietin can be detected by bioassay using either its effects on T cell differen-tiation or neuromuscular transmission, these assays are complex, time-consuming, and difficult to standardize. Moreover, unlike immunoassay, and particularly radioimmunoassay, bioassays are not readily automated and thus could not be routinely employed by clinical laboratories or other diagnostic facilities to screen large numbers of samples in an economic fashion.
DESCRIPTION OF lHE INVENTION
.
The present invention relates to an immunoassay for thymopoie-tin. A pre-ferred immunoassay can give sensitivities ZO ; down to about O.1 ng/ml. of -the hormone in biological fluid samples such as plasma or serum. Thus the instant assay can be employed as a diagnostic test for disease states which exhibit either elevated (myasthenia gravis) or reduced (aging, immune deficiency or immunologically mediated diseases, cancer, malnutrition, infect1ons and the like) levels of thymopoietin. The two forms of thymopoietin are indistinguishable in immunoassay procedures. ;
The antigen utilized~to prepare the antibody ~or the instant~assay is readily obtained by bonding thymopoietin to ~-an 1mmunogenlc carrier mater1al 1n a manner known per se. Such -bonding is pre~erably achieved by employing a suitable bifunctional ~ ;
l1nking graup. A preferred bifunctional linking group for this purpose 1S a C2 7 dialkanal such as glutaraldehyde.
- 2 -.. ~
~S60~
As used herein the term "immunogenic carrier ma-terial"
is meant to include those materials which have the property of independently eliciting an immunogenic response in a host animal and which can be coupled to thymopoietin. Suitable carrier materials include for example, proteins; na-tural or synthetic polymeric compounds such as polypeptides, e.g., polylysine or copolymers of amino acids; polysaccharides; and the like. Particularly preferred carrier materials are proteins and polypeptides, ~specially pro-teins. `~
The identity of the protein material utilized in the preparation of an antigen of the instant invention is not critical. Examples o~ suitable proteins useul in the practice o this invention include mammalian serum proteins such as, for example, human gamma globulin, human serum albumin, bovine serum albumin, methylated bovine serum albumin, rabbit serum albumin, bovine gamma globulin and equine gamma globulin. Other suitable proteins will be suggested to one skilled in the art.
It is yenerally preferred but not necessary that proteins be utilized which are foreign to the animal hosts in which the resulting antigen will be employed.
The coupling of thymopoietin to the immunogenic carrier material can be carried out in a m~nner well known in the art. Preferred procedures comprise use of covalent bonding or physical bonding, e.g. electrostatically. Thus, for example, when the coupling is carried out to achieve covalent bonding, use of a bifunctional linking group such as glutaraldehyde under the conditions described by S. Avrameas, Immunochemistry 6, 43 (1969) may be employed.
While use o a bifunctional linking group is the preferred manner of achieving covalent bonding of thymopoietin to the immunogenic carrier materialj other methods for ' , :1~7~
bonding may also be utilized. In one such method, use may be made of the carbodiimide technique as described in "Science", Vol. 14, pages 1344-1346, June 12, 1964. As reported in this article, carbodiimides can be used to couple materials containing many types of functional yroups including carboxylic acids and amines. In this alternate method, coupling proceeds to form covalent bonds by coupling of the thymopoietln to the protein through an amide linkage in the manner described in this article from "Scien~e". A further method of covalent bondiny~.
utilizing cyanates which may be used is described in U.S.
Patent No. 3,788,948, issued January 29, 1974.
Bonding of ~he thymopoietin to the carrier may also -be achieved by physical means, for example, by electrostatic bonding, using means known to those skilled in the art. This method proceeds by formation of a complex between the carrier and thymopoietin and may be carried out as described in "Methods in Immunology and Immunochemistry", edited by Curtis A. Williams, ~ -Vol. I, Academic Press, (1967). Other methods are described in United States Patent No. 3,853,987, issued December 10, 1974.
It is,of course, to be understood that other methods known to those skilled in the art may be employed to bond the thymopoietin to the carrier.
The antigens of the present invention may be utilized to induce formation of antibodies specific to thymopoietin in host animals by injecting the antigen in such a hostl preferably using an adjuvant such as Freund's adjuvant, using known methods.
Improved titres can be obtained by repeated injections over a period of time. Suitable host animals for this purpose include mammals such as rabbits, hoxses, goats, guinea pigs, rats, cows, sheep, etc. The resulting antisera will contain antibodies which will selectively complex with thymopoietin or an antigen prepared therefrom, as described above.
, ., ~.
.
. . . i ...... ., .................. -~0~560~
The specific antibodies for thymopoietin prepared in accordance with the present invention are usefu] as reagents in an immunoassay for thymopoietin. In a preferred embodiment, antiserum diluted in a sui-table buffer such as 5% bovine gamma globulin in 0.1 M phosphate - buffered normal saline, pH 7.4 (BGG - buffer) is mixed with a standard or test sample and also a known amount of radiolabeled thymopoietin, both being dissolved in BGG buffer.
Various methods can then be utilized to determine the amount of thymopoietin present in the test sample. In a first technique, after mixing of the above components and allowing the mixture to stand for several hours at room temperature, the anti-body - antigen complex was precipitated using cold 30~ poly-ethylene glycol. After centrifugation, the supernatant is aspirated and the radioactivity in the precipitate counted. The thymopoietin content of the sample can then be determined by comparing the radioactivity level observed to a standard curve in a manner known per se. A suitable standard curve can be obtained by mixing known amounts of thymopoietin with fixed amounts of labeled thymopoietin and the thymopoietin specific antibody and determining the degree of binding for each known amount.
Alternate separation systems for removing the antigen-antibody complex may be employed. Such alternate systems are in fact preferred over the polyethylene glycol system described above as they yield greater sensitivity for the assay.
One such system involves the use of a double antibody technique. After the incubation of the three component assay re-action mixture as described above, an antibody elicited in another
~S60~
As used herein the term "immunogenic carrier ma-terial"
is meant to include those materials which have the property of independently eliciting an immunogenic response in a host animal and which can be coupled to thymopoietin. Suitable carrier materials include for example, proteins; na-tural or synthetic polymeric compounds such as polypeptides, e.g., polylysine or copolymers of amino acids; polysaccharides; and the like. Particularly preferred carrier materials are proteins and polypeptides, ~specially pro-teins. `~
The identity of the protein material utilized in the preparation of an antigen of the instant invention is not critical. Examples o~ suitable proteins useul in the practice o this invention include mammalian serum proteins such as, for example, human gamma globulin, human serum albumin, bovine serum albumin, methylated bovine serum albumin, rabbit serum albumin, bovine gamma globulin and equine gamma globulin. Other suitable proteins will be suggested to one skilled in the art.
It is yenerally preferred but not necessary that proteins be utilized which are foreign to the animal hosts in which the resulting antigen will be employed.
The coupling of thymopoietin to the immunogenic carrier material can be carried out in a m~nner well known in the art. Preferred procedures comprise use of covalent bonding or physical bonding, e.g. electrostatically. Thus, for example, when the coupling is carried out to achieve covalent bonding, use of a bifunctional linking group such as glutaraldehyde under the conditions described by S. Avrameas, Immunochemistry 6, 43 (1969) may be employed.
While use o a bifunctional linking group is the preferred manner of achieving covalent bonding of thymopoietin to the immunogenic carrier materialj other methods for ' , :1~7~
bonding may also be utilized. In one such method, use may be made of the carbodiimide technique as described in "Science", Vol. 14, pages 1344-1346, June 12, 1964. As reported in this article, carbodiimides can be used to couple materials containing many types of functional yroups including carboxylic acids and amines. In this alternate method, coupling proceeds to form covalent bonds by coupling of the thymopoietln to the protein through an amide linkage in the manner described in this article from "Scien~e". A further method of covalent bondiny~.
utilizing cyanates which may be used is described in U.S.
Patent No. 3,788,948, issued January 29, 1974.
Bonding of ~he thymopoietin to the carrier may also -be achieved by physical means, for example, by electrostatic bonding, using means known to those skilled in the art. This method proceeds by formation of a complex between the carrier and thymopoietin and may be carried out as described in "Methods in Immunology and Immunochemistry", edited by Curtis A. Williams, ~ -Vol. I, Academic Press, (1967). Other methods are described in United States Patent No. 3,853,987, issued December 10, 1974.
It is,of course, to be understood that other methods known to those skilled in the art may be employed to bond the thymopoietin to the carrier.
The antigens of the present invention may be utilized to induce formation of antibodies specific to thymopoietin in host animals by injecting the antigen in such a hostl preferably using an adjuvant such as Freund's adjuvant, using known methods.
Improved titres can be obtained by repeated injections over a period of time. Suitable host animals for this purpose include mammals such as rabbits, hoxses, goats, guinea pigs, rats, cows, sheep, etc. The resulting antisera will contain antibodies which will selectively complex with thymopoietin or an antigen prepared therefrom, as described above.
, ., ~.
.
. . . i ...... ., .................. -~0~560~
The specific antibodies for thymopoietin prepared in accordance with the present invention are usefu] as reagents in an immunoassay for thymopoietin. In a preferred embodiment, antiserum diluted in a sui-table buffer such as 5% bovine gamma globulin in 0.1 M phosphate - buffered normal saline, pH 7.4 (BGG - buffer) is mixed with a standard or test sample and also a known amount of radiolabeled thymopoietin, both being dissolved in BGG buffer.
Various methods can then be utilized to determine the amount of thymopoietin present in the test sample. In a first technique, after mixing of the above components and allowing the mixture to stand for several hours at room temperature, the anti-body - antigen complex was precipitated using cold 30~ poly-ethylene glycol. After centrifugation, the supernatant is aspirated and the radioactivity in the precipitate counted. The thymopoietin content of the sample can then be determined by comparing the radioactivity level observed to a standard curve in a manner known per se. A suitable standard curve can be obtained by mixing known amounts of thymopoietin with fixed amounts of labeled thymopoietin and the thymopoietin specific antibody and determining the degree of binding for each known amount.
Alternate separation systems for removing the antigen-antibody complex may be employed. Such alternate systems are in fact preferred over the polyethylene glycol system described above as they yield greater sensitivity for the assay.
One such system involves the use of a double antibody technique. After the incubation of the three component assay re-action mixture as described above, an antibody elicited in another
3~ mammalian species against the primary assay antibody is added, the components mixed, then after standing 5 up to 120 minutes at room temperature, the mixture is centri~uged. After aspiration ~17~60~`
of the supernatant, the precipitate is counted for radioactivity and the thymopoietin level in the sample determined from a standard curve as above.
The other alternative system employs dextran coated charcoal to assist in separation of the antibody-a}ltigen complex.
In this technique, dextran coated charcoal is added to the assay reaction system after incubation. A xeduced temperature of about 4C. is utilized. After standing at about 4C. for about 30 minutes the mixture is centrifuged and the supernatant aspirated.
The precipitate is counted for radioactivity, which in this technique represents "unbound"~thymopoietin.
In preferred embodiments of the present assay systems the normal saline utilized in the BGG buffer system is replaced with 4M KCl. This substitution reduces non-specific binding in the assay without concomitank loss of sensitivity.
Suitable labeled thymopoietins for use in the immuno-assay of the present invention include radioisotopically labeled thymopoietins, particularly those labeled with tritium (3H), carbon 14(14 C), iodine 125 (125~), or with iodine 131(131I).
For other immunoassay embodiments i~ accordance with this invention one may employ thymopoietins labeled with any other unique and detectable label such as for example chromophores, fluorophors, enzymes, red blood cells, latex partiales or electron spin ~
resonance groups. -A most preferred radiolabeled thymopoietin is 1 thymopoietin. The introduction of the 125I label into thymopoietin can he carried out by procedures known in the art such as by using the chloramine-T method, or more preferably by using the Bolton-~unter reagent (125I iodinated p-hydroxyphenylpropionic acid, N-hydroxysuccinlmlde ester) as described in Biochem. J. 133, 529 (1973~. This preference is based on the fact ~hat direct ~756(~
iodination of the tyrosyl moieties of thymopoietin results in some loss of immunoreactivityO However, since the Bolton-Hunter reagent condenses with free amino groups it does not affect the immunodeterminant tyrosyl regions.
The remaining above-mentioned labeled thymopoietins are prepared by means known to those skilled in the art. For example, enzyme labeled thymopoietins may be prepared as described in United States Patent No. 3,654,090, issued April 4, 1972.
Also, United St~ates~Patent No. 3,853,987, issued December 10,`~1974, describes methods for use of tracer materials such as fluorescent compounds and latex systems for labeling. Accordingly, such methods of labeling are fully described in the prior art. Thus labeled thymopoietins of the present invention include those radioisotopically labeled, as well as thymopoietins labeled with lS the other materials mentioned. ,! "
The immunoassay of this irvention was shown to be l . I
specific ior thymopoietin by testing with various control polypeptides and observing no displacement of the antibody-labeled antigen complex. In particular no cross-reaction was obtained with ubiquitin, a material which is widespread in tissues, and with histones, which are extrac~d from bovine thymus. A
synthetic tridecapeptide based on residues"29-41 of thymopoietin, which has the biological activities of -thymopoietin did not cross react; apparently this region lacks either the residues and/or the tertiary structure required to reconstitute the antigenic sites recognized by the antithymopoietin antibodies in the antiserum.
The present invention is further illustrated by the following examples.
Antigen and Antibody Prepara-tion Thymopoietin was isolated as described by Goldstein, Nature 247, 11 ~1974)~ For immunization, it was coupled to an . . - ~
~ al7S6(~
equal weight of equine gamma globulin with glutaradehyde as the coupling reagent according to -the procedure of Avrameas, Immunochemistry 6, 43 (1969). The resulting antigen was then employed in preparing thymopoietin antibody.
Three female San Juan rabbits were each immunized with 400 ~g of thymopoietin antigen emulsified in Freunds complete adjuvant and injected intradermally in multiple sites.
Immunization was repeated four ti.mes at bi-weekly intervals and the animals were bled one week after the last injections.
,~
Radiolabeliny of Thymopoietin (a) Chloram1ne-T Procedure Thymopoietin was further purified on carboxy-methyl-Sephadex~ CM-Sephadex) (0.6 x 30 cm column) equilibrated in 0.2 M ammonium acetate, pH 4.5 and developed with a linear gradient to 0.5 M, pH 4.5. Thymopoietin appeared closely behind the void volume and these fractions were lyophilized and desalted on Sephadex G-25. Purity was established by polyacrylamide gel electrophoresis at pH 4.3 and pH 8.9.
Ten micrograms of the highly purified thymopoietin was radiolabeled with 2 mCi carrier free 125I by the chloramine method o Hunter and Greenwood, Nature, 194, 495 (1962) and 1 5I thymopoietin was separated from unreacted radionuclides on Sephadex G-25 ~0.6 x 30 cm column) in 0.05 M phosphate, pH 7.5. The column was prewashed with 0.25% gelatin in phosphate buffer. The radioactivity of 1 ~lsample from each fraction was determined in an automated gamma spectrometer and the fraction corresponding to the void volume was divided into 0.1 ml.
aliquots and stored at -20C. for use within three weeks.
~07S~
(b) Bolton-Hunter Procedure Two millicuries of 125I iodinated p-hydroxy-phenylpropionic acid N-hydroxysuccinimide ester (Bolton-~unter reagent ~1500 Ci/mmole) dissolved in benzene were utilized to iodinate thymopoietin at 4C. by the procedure described by Bolton and Hunter, Biochem. J. 133, 529 (1973). The Bolton-Hunter reagent was dried in a fume hood by passing a stream of nitrogen over t~e mouth of the vial and 10 ~1 of thymopoie~tin (0.5 mg/ml. in 0.1 M sodium borate, pH 8.5) were added and held at 4C. for 45 minutes. Half milliliter of-0.2M ~lycine i~
O.1 M sodium borate, pH 8.5 was then added to react with unconjugated reagent. After 15 minutes I thymopoietin was separated from the other Iabeled products of the conjugation by the method described in (a) above.
Only 5% of thymopoietin radioiodinated by the chloramine-T method were bound in the prçsence of excess antibody, this binding decreasing at dilutions greater than 10 . By contrast 45~ of thymopoietin radioiodinated by the solton-Hunter method was bound in the presence of excess antibody; this binding also decreased at antibody dilutions greater than 10 3.
ta) Radioimmunoassay-Polyethylene Glycol Separation Incubations were carried out in triplicate in 12 x 75 mm plastic tubes. To 0.5 ml. of antiserum diluted in 5%
bovine gamma globulin in 0.01M phosphate-buffered 0~15M NaCl (BGG buffer) was added 0.2 ml. of sample and 0O3 ml. of 125I-thymopoietin (~50,000 cpm in BGG buffer). When serum samples are to be assayed they are prepared by molecular sieve _ g _ .: , ;,.. ~: ,~
.. . ~
,, . ~ . . .. . .
:~63756~
chromatography on G-50 Sephadex in O.lM ammonium bicarbona-te, pH 8Ø The fractions behind the excluded volumn (Vo) and ahead of the included volumne (Vi) are pooled and lyophilized and -the resulting powder -taken up in buffer for thymopoietin. This preparation serves to exclude molecules of molecular weights higher or lower than thymopoietin from t~e assay.
The a~ssay tubes are agitated on a vortex mixer and left standing for two hours at room temperature. Half milliliter of cold 30% polyethylene gl~col was then added ~ ~-to each tube which was agitated on a vortex mixer and centrifuged at 2,000 rpm in a refrigerated centrifuge for 30 minutes. The supernatants were aspirated and the radioactivity in the preci~itates was determined in an automated lS gamma spectrometer. 125I thymopoietin precipi-tated (%) was calculated according to the formula a-c (b-c) x 100 where a = cpm precipitated with antibody, b - total cpm added, and c = cpm precipitated nonspecifically with normal rabbit serum or with antibody and excess unlabeled thymopoietin (these were usually approximately 10~ of total cpm). For the standard curve of binding inhibition the thymopoietin bound was calculated as a percentage of maximal thymopoietin binding with antibody at 10 1. An antibody dilution of 1:3000 was used for the standard curve of binding inhibition.
':
' 25 (b) Radioimmunoassay - Double ~ntibody Separation The procedure of (a) above was repeated except '. . .,: .
! that 4M KC~ BGG buffer was used and after the two hour incubation period a total of 0.1 ml. of goat anti-rabbit antibody and 0.02 ml. of normal rabbit were added, the components .:
.. . . ,, , , . :
~75~
mixed on a vortex mixer, the resulting mixture was allowed to stand at room temperature for 5 minutes and then was centrifuged. The supernatant was aspirated and the precipitate was counted for radioactivity as in (a) above.
(c) Radioimmunoassay - Dextran Coated Charcoal Separation Dextran coated charcoal is prepared by mixing equal volumes of (i) 5 gm of Nori-t A charcoal per 100 ml of phosphate buffer containing 2MKCl and bovine gan~a globulin and (ii) 0.5 gm of dextran 110 per 100 ml. of phosphate buffer ~ , containing lM KCl and bovine gamma globulin.
A total 0.5 ml. of dex-tran coated charcoal is added at 4C. to the assay tube after -the two hour incubation as in (b) above and the mixture allowed to stand at 4C. for 30 minutes. The tubes are centrifuged and the supernatants aspirated. The pellets are counted for radioactivity which represents "unbound" thymopoietin in this assay~
The binding-inhibition standard curve for unlabeled thymopoietin in the assay employing polyethylene glycol separation of the antigen-antibody complex showed sensitivity to thymopoietin concentrations greater than 5 ng/ml. No significant displacement was produced by control polypeptides which included insulin, alpha-bungarokoxin, ubi~uitin, histone and a synthetic tridecapeptide fragment of thymopoietin (residues 29-41) at concentrations of 10 to 1,000 ng./ml.
Binding-inhibition curves for unlabeled thymopoietin in the assays employing the double antibody and dextran ~oated charcoal s~paration of the antigen-antibody complex both showed sensitivity to thymopoietin concentrations down to 0.1 ng thymopoietin/ml. These latter two procedures are thus especially suitable for measuring thymopoietin levels in serum samplesO ' ,. . ... . ..
.. . . . . .
,, . . . :
of the supernatant, the precipitate is counted for radioactivity and the thymopoietin level in the sample determined from a standard curve as above.
The other alternative system employs dextran coated charcoal to assist in separation of the antibody-a}ltigen complex.
In this technique, dextran coated charcoal is added to the assay reaction system after incubation. A xeduced temperature of about 4C. is utilized. After standing at about 4C. for about 30 minutes the mixture is centrifuged and the supernatant aspirated.
The precipitate is counted for radioactivity, which in this technique represents "unbound"~thymopoietin.
In preferred embodiments of the present assay systems the normal saline utilized in the BGG buffer system is replaced with 4M KCl. This substitution reduces non-specific binding in the assay without concomitank loss of sensitivity.
Suitable labeled thymopoietins for use in the immuno-assay of the present invention include radioisotopically labeled thymopoietins, particularly those labeled with tritium (3H), carbon 14(14 C), iodine 125 (125~), or with iodine 131(131I).
For other immunoassay embodiments i~ accordance with this invention one may employ thymopoietins labeled with any other unique and detectable label such as for example chromophores, fluorophors, enzymes, red blood cells, latex partiales or electron spin ~
resonance groups. -A most preferred radiolabeled thymopoietin is 1 thymopoietin. The introduction of the 125I label into thymopoietin can he carried out by procedures known in the art such as by using the chloramine-T method, or more preferably by using the Bolton-~unter reagent (125I iodinated p-hydroxyphenylpropionic acid, N-hydroxysuccinlmlde ester) as described in Biochem. J. 133, 529 (1973~. This preference is based on the fact ~hat direct ~756(~
iodination of the tyrosyl moieties of thymopoietin results in some loss of immunoreactivityO However, since the Bolton-Hunter reagent condenses with free amino groups it does not affect the immunodeterminant tyrosyl regions.
The remaining above-mentioned labeled thymopoietins are prepared by means known to those skilled in the art. For example, enzyme labeled thymopoietins may be prepared as described in United States Patent No. 3,654,090, issued April 4, 1972.
Also, United St~ates~Patent No. 3,853,987, issued December 10,`~1974, describes methods for use of tracer materials such as fluorescent compounds and latex systems for labeling. Accordingly, such methods of labeling are fully described in the prior art. Thus labeled thymopoietins of the present invention include those radioisotopically labeled, as well as thymopoietins labeled with lS the other materials mentioned. ,! "
The immunoassay of this irvention was shown to be l . I
specific ior thymopoietin by testing with various control polypeptides and observing no displacement of the antibody-labeled antigen complex. In particular no cross-reaction was obtained with ubiquitin, a material which is widespread in tissues, and with histones, which are extrac~d from bovine thymus. A
synthetic tridecapeptide based on residues"29-41 of thymopoietin, which has the biological activities of -thymopoietin did not cross react; apparently this region lacks either the residues and/or the tertiary structure required to reconstitute the antigenic sites recognized by the antithymopoietin antibodies in the antiserum.
The present invention is further illustrated by the following examples.
Antigen and Antibody Prepara-tion Thymopoietin was isolated as described by Goldstein, Nature 247, 11 ~1974)~ For immunization, it was coupled to an . . - ~
~ al7S6(~
equal weight of equine gamma globulin with glutaradehyde as the coupling reagent according to -the procedure of Avrameas, Immunochemistry 6, 43 (1969). The resulting antigen was then employed in preparing thymopoietin antibody.
Three female San Juan rabbits were each immunized with 400 ~g of thymopoietin antigen emulsified in Freunds complete adjuvant and injected intradermally in multiple sites.
Immunization was repeated four ti.mes at bi-weekly intervals and the animals were bled one week after the last injections.
,~
Radiolabeliny of Thymopoietin (a) Chloram1ne-T Procedure Thymopoietin was further purified on carboxy-methyl-Sephadex~ CM-Sephadex) (0.6 x 30 cm column) equilibrated in 0.2 M ammonium acetate, pH 4.5 and developed with a linear gradient to 0.5 M, pH 4.5. Thymopoietin appeared closely behind the void volume and these fractions were lyophilized and desalted on Sephadex G-25. Purity was established by polyacrylamide gel electrophoresis at pH 4.3 and pH 8.9.
Ten micrograms of the highly purified thymopoietin was radiolabeled with 2 mCi carrier free 125I by the chloramine method o Hunter and Greenwood, Nature, 194, 495 (1962) and 1 5I thymopoietin was separated from unreacted radionuclides on Sephadex G-25 ~0.6 x 30 cm column) in 0.05 M phosphate, pH 7.5. The column was prewashed with 0.25% gelatin in phosphate buffer. The radioactivity of 1 ~lsample from each fraction was determined in an automated gamma spectrometer and the fraction corresponding to the void volume was divided into 0.1 ml.
aliquots and stored at -20C. for use within three weeks.
~07S~
(b) Bolton-Hunter Procedure Two millicuries of 125I iodinated p-hydroxy-phenylpropionic acid N-hydroxysuccinimide ester (Bolton-~unter reagent ~1500 Ci/mmole) dissolved in benzene were utilized to iodinate thymopoietin at 4C. by the procedure described by Bolton and Hunter, Biochem. J. 133, 529 (1973). The Bolton-Hunter reagent was dried in a fume hood by passing a stream of nitrogen over t~e mouth of the vial and 10 ~1 of thymopoie~tin (0.5 mg/ml. in 0.1 M sodium borate, pH 8.5) were added and held at 4C. for 45 minutes. Half milliliter of-0.2M ~lycine i~
O.1 M sodium borate, pH 8.5 was then added to react with unconjugated reagent. After 15 minutes I thymopoietin was separated from the other Iabeled products of the conjugation by the method described in (a) above.
Only 5% of thymopoietin radioiodinated by the chloramine-T method were bound in the prçsence of excess antibody, this binding decreasing at dilutions greater than 10 . By contrast 45~ of thymopoietin radioiodinated by the solton-Hunter method was bound in the presence of excess antibody; this binding also decreased at antibody dilutions greater than 10 3.
ta) Radioimmunoassay-Polyethylene Glycol Separation Incubations were carried out in triplicate in 12 x 75 mm plastic tubes. To 0.5 ml. of antiserum diluted in 5%
bovine gamma globulin in 0.01M phosphate-buffered 0~15M NaCl (BGG buffer) was added 0.2 ml. of sample and 0O3 ml. of 125I-thymopoietin (~50,000 cpm in BGG buffer). When serum samples are to be assayed they are prepared by molecular sieve _ g _ .: , ;,.. ~: ,~
.. . ~
,, . ~ . . .. . .
:~63756~
chromatography on G-50 Sephadex in O.lM ammonium bicarbona-te, pH 8Ø The fractions behind the excluded volumn (Vo) and ahead of the included volumne (Vi) are pooled and lyophilized and -the resulting powder -taken up in buffer for thymopoietin. This preparation serves to exclude molecules of molecular weights higher or lower than thymopoietin from t~e assay.
The a~ssay tubes are agitated on a vortex mixer and left standing for two hours at room temperature. Half milliliter of cold 30% polyethylene gl~col was then added ~ ~-to each tube which was agitated on a vortex mixer and centrifuged at 2,000 rpm in a refrigerated centrifuge for 30 minutes. The supernatants were aspirated and the radioactivity in the preci~itates was determined in an automated lS gamma spectrometer. 125I thymopoietin precipi-tated (%) was calculated according to the formula a-c (b-c) x 100 where a = cpm precipitated with antibody, b - total cpm added, and c = cpm precipitated nonspecifically with normal rabbit serum or with antibody and excess unlabeled thymopoietin (these were usually approximately 10~ of total cpm). For the standard curve of binding inhibition the thymopoietin bound was calculated as a percentage of maximal thymopoietin binding with antibody at 10 1. An antibody dilution of 1:3000 was used for the standard curve of binding inhibition.
':
' 25 (b) Radioimmunoassay - Double ~ntibody Separation The procedure of (a) above was repeated except '. . .,: .
! that 4M KC~ BGG buffer was used and after the two hour incubation period a total of 0.1 ml. of goat anti-rabbit antibody and 0.02 ml. of normal rabbit were added, the components .:
.. . . ,, , , . :
~75~
mixed on a vortex mixer, the resulting mixture was allowed to stand at room temperature for 5 minutes and then was centrifuged. The supernatant was aspirated and the precipitate was counted for radioactivity as in (a) above.
(c) Radioimmunoassay - Dextran Coated Charcoal Separation Dextran coated charcoal is prepared by mixing equal volumes of (i) 5 gm of Nori-t A charcoal per 100 ml of phosphate buffer containing 2MKCl and bovine gan~a globulin and (ii) 0.5 gm of dextran 110 per 100 ml. of phosphate buffer ~ , containing lM KCl and bovine gamma globulin.
A total 0.5 ml. of dex-tran coated charcoal is added at 4C. to the assay tube after -the two hour incubation as in (b) above and the mixture allowed to stand at 4C. for 30 minutes. The tubes are centrifuged and the supernatants aspirated. The pellets are counted for radioactivity which represents "unbound" thymopoietin in this assay~
The binding-inhibition standard curve for unlabeled thymopoietin in the assay employing polyethylene glycol separation of the antigen-antibody complex showed sensitivity to thymopoietin concentrations greater than 5 ng/ml. No significant displacement was produced by control polypeptides which included insulin, alpha-bungarokoxin, ubi~uitin, histone and a synthetic tridecapeptide fragment of thymopoietin (residues 29-41) at concentrations of 10 to 1,000 ng./ml.
Binding-inhibition curves for unlabeled thymopoietin in the assays employing the double antibody and dextran ~oated charcoal s~paration of the antigen-antibody complex both showed sensitivity to thymopoietin concentrations down to 0.1 ng thymopoietin/ml. These latter two procedures are thus especially suitable for measuring thymopoietin levels in serum samplesO ' ,. . ... . ..
.. . . . . .
,, . . . :
Claims (21)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An antigen consisting essentially of thymopoietin bonded to an immunogenic carrier material.
2. An antigen according -to claim 1 wherein bonding of said thymopoietin to said carrier material is by covalent bonding.
3. An antigen according to claim 1 wherein said covalent bonding is through a bifunctional linking group.
4. The antigen of claim 3 wherein said bifunctional linking group is a C2-7 dialkanal.
5. The antigen of claim 4 wherein said C2-7 dialkanal is glutaraldehyde.
6. The antigen of claim 1 wherein said immunogenic carrier material is a protein.
7. The antigen of claim 6 wherein said protein is a mammalian gamma globulin.
8. The antigen of claim 6 wherein said protein is bovine serum albumin.
9. An antibody specific to thymopoietin and to an antigen consisting essentially of thymopoietin bonded to an immunogenic carrier material, said thymopoietin specific antibody being prepared by innoculating a host animal with the aforesaid antigen and collecting the serum from said host animal.
10. The antibody of claim 9 wherein said antigen consists of thymopoietin covalently bonded to a protein.
11. The antibody of claim 10 wherein said covalent bonding is by a bifunctional linking group.
12. The antibody of claim 10 wherein said protein selected from the group consisting of equine gamma globulin and bovine serum albumin and said bifunctional linking group is glutaraldehyde.
13. Labeled thymopoietin, wherein the label is selected from the group consisting of tritium, carbon 14, iodine 131, iodine 125, chromophores, fluorophors, enzymes, red blood cells, latex particles and electron spin resonance groups.
14. Labeled thymopoietin according to claim 13 wherein the label is 125I.
15. A method for the assay of thymopoietin in a sample, which method comprises mixing said sample with a known amount of labeled thymopoietin and an antibody which will selectively complex with said thymopoietin, separating the resulting antibody-antigen complex from the supernatant, measuring the degree of binding of the said labeled thymopoietin in said complex and determining the amount of thymopoietin present in said sample by comparing said degree of binding to a standard curve obtained by mixing known amounts of thymopoietin with fixed amounts of said labeled thymopoietin and said antibody and determining the degree of binding for each known amount of thymopoietin.
16. The method of claim 15 wherein a radioimmunoassay is employed and radiolabeled thymopoietin is used.
17. The method of claim 16 wherein the antibody-antigen complex is separated from solution with the assistance of 30% polyethylene glycol.
18. The method of claim 16 wherein the antibody-antigen complex is separated from solution with the assistance of a double antibody technique using an antibody against the serum of the host animal in which the thymopoietin antibody was elicited.
19. The method of claim 16 wherein the antibody-antigen complex is separated from solution with the assistance of a dextran coated charcoal technique wherein the radioactivity of the precipitate represents unbound thymopoietin.
20. The method of claim 16 wherein said radiolabeled thymopoietin is I125-thymopoietin.
21. The method of claim 16 wherein the sample being assayed is a plasma or serum sample.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/709,565 US4055633A (en) | 1976-07-28 | 1976-07-28 | Immunoassay for thymopoietin |
| US05/810,269 US4124700A (en) | 1976-07-28 | 1977-06-27 | Immunoassay for thymopoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1075600A true CA1075600A (en) | 1980-04-15 |
Family
ID=27108277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA282,819A Expired CA1075600A (en) | 1976-07-28 | 1977-07-15 | Immunoassay for thymopoietin |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS6012576B2 (en) |
| AU (1) | AU497627B1 (en) |
| CA (1) | CA1075600A (en) |
| DE (1) | DE2733561C3 (en) |
| FR (1) | FR2359851A1 (en) |
| GB (1) | GB1545332A (en) |
| IT (1) | IT1126757B (en) |
| NZ (1) | NZ184667A (en) |
| SE (1) | SE447165B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2557458B1 (en) * | 1983-12-30 | 1987-09-04 | Centre Nat Rech Scient | NOVEL ANTIBODIES CAPABLE OF SPECIFICALLY RECOGNIZING HAPTENIC GROUPS, THEIR PREPARATION AND THEIR APPLICATION, AND NOVEL ANTIGENS FOR PREPARING THEM |
| GB2160312B (en) * | 1984-04-13 | 1987-09-16 | South African Inventions | Adjuvant for immunisation |
| FR2581313A1 (en) * | 1985-05-02 | 1986-11-07 | Pasteur Institut | COMPOUNDS FOR ANTIBODY FORMATION, IMMUNOGENIC COMPOSITIONS AND IMMUNOPROTECTIVE COMPOSITIONS CONTAINING SAME, AND METHOD FOR OBTAINING ANTIBODIES USING SAME |
| US5593842A (en) * | 1994-09-20 | 1997-01-14 | Gideon Goldstein | Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum |
-
1977
- 1977-07-15 CA CA282,819A patent/CA1075600A/en not_active Expired
- 1977-07-18 NZ NZ18466777A patent/NZ184667A/en unknown
- 1977-07-19 GB GB3017777A patent/GB1545332A/en not_active Expired
- 1977-07-26 IT IT5044677A patent/IT1126757B/en active
- 1977-07-26 DE DE19772733561 patent/DE2733561C3/en not_active Expired
- 1977-07-27 FR FR7723092A patent/FR2359851A1/en active Granted
- 1977-07-27 JP JP9021277A patent/JPS6012576B2/en not_active Expired
- 1977-07-27 SE SE7708625A patent/SE447165B/en not_active IP Right Cessation
- 1977-07-27 AU AU27382/77A patent/AU497627B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6012576B2 (en) | 1985-04-02 |
| DE2733561C3 (en) | 1980-04-03 |
| SE7708625L (en) | 1978-01-29 |
| JPS5459318A (en) | 1979-05-12 |
| SE447165B (en) | 1986-10-27 |
| NZ184667A (en) | 1980-02-21 |
| GB1545332A (en) | 1979-05-10 |
| FR2359851B1 (en) | 1983-04-01 |
| IT1126757B (en) | 1986-05-21 |
| AU497627B1 (en) | 1978-12-21 |
| DE2733561B2 (en) | 1979-07-26 |
| DE2733561A1 (en) | 1978-02-02 |
| FR2359851A1 (en) | 1978-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Theofilopoulos et al. | The nature of immune complexes in human cancer sera | |
| CA1225590A (en) | Use of anti-idiotype antibodies in immunoassays | |
| Kakumu et al. | Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases | |
| US4312853A (en) | Radioimmunological determination of procollagen (type III) and procollagen peptide (type III) | |
| JPH06317589A (en) | Immunoassay method, from which assay interference is excluded, and kit | |
| WO1983004312A1 (en) | Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays | |
| US4124700A (en) | Immunoassay for thymopoietin | |
| US4264571A (en) | Radioimmunoassay of thymosin α1 | |
| US4489167A (en) | Methods and compositions for cancer detection | |
| Mercham et al. | [42] Antibodies to insoluble and solubilized elastin | |
| Goldstein | Radioimmunoassay for thymopoietin | |
| JP3362054B2 (en) | Squamous cell carcinoma and its separation method | |
| EP0020090B1 (en) | Radioimmunoassay of migration inhibitory factor | |
| FI95579C (en) | Method for selective immunologic determination of intact procollagen peptide (type III) and procollagen (type III) in body fluids and agents for carrying out this | |
| US5324822A (en) | Method of isolating a CA 195-like immunoreactive antigen from human amniotic fluid | |
| CA1075600A (en) | Immunoassay for thymopoietin | |
| Grassi et al. | Two different approaches for developing immunometric assays of haptens | |
| EP0245052A2 (en) | Detection of inflammation and novel antibodies therefor | |
| US4792528A (en) | Methods for obtaining monoclonal antibodies useful in enhanced sensitivity immunoassays | |
| US4096237A (en) | Immunoassay for β-endorphin | |
| Suzuta | Therapeutic and diagnostic applications of latex-bound immunoglobulins | |
| Kilgallon et al. | Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes. | |
| JPH07110879B2 (en) | Monoclonal antibody | |
| JPS6212859A (en) | Specific bacterial polypeptide and determination method of antibody to said polypeptide | |
| AU639022B2 (en) | Antibodies against highly conserved amino acid sequences of immunogenic substances, a process for the preparation of these antibodies and the use thereof in immunoassays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |